Friday, March 17, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Antimicrobial Resistance

Soligenix to Present at Chemical and Biological Defense S&T Conference

by Global Biodefense Staff
May 4, 2015
DTRA CBD S&T Conference Logo

Soligenix announced today that it will be presenting preclinical data from three of its biodefense programs at the upcoming Chemical and Biological Defense Science and Technology Conference on May 12-14, 2015 in St. Louis, Mo.

The presented results will address recent preclinical efficacy findings in three programs, including:

  • SGX943 in the treatment of antibiotic resistant infections including melioidosis
  • RiVax, a proprietary thermostable ricin toxin vaccine, in an inhalational model of ricin intoxication, and
  • VeloThrax, a proprietary thermostable anthrax toxin vaccine.

SGX943 is based on Soligenix’s SGX94 technology, an Innate Defense Regulator, which enhances the anti-infective activity of the innate immune system while modulating inflammation. Since SGX943 does not directly target the bacteria, it is unlikely to engender resistance and is complementary with current antibiotic regimens.

RiVax is the company’s candidate vaccine for the prevention of exposure to ricin toxin using a unique antigen that is completely devoid of the toxic activity of ricin. When formulated with Soligenix’s proprietary ThermoVax technology, RiVax has demonstrated significantly enhanced thermostability and 100% protection in preclinical aerosol challenge models.

VeloThrax is the company’s candidate vaccine for the prevention of exposure to anthrax using the Dominant Negative Inhibitor (DNI) of the recombinant protective antigen (rPA) of anthrax. When formulated with Soligenix’s proprietary ThermoVax technology, VeloThrax has demonstrated significantly enhanced thermostability and compatibility with secondary adjuvants such as TLR-4 agonists, facilitating more rapid onset of immunity.

Preclinical studies for SGX943, RiVax, and VeloThrax were supported by grant awards from the National Institute of Allergy and Infectious Diseases (NIAID).

Oral and poster presentations involving Soligenix products include:

  • Innate Defense Regulators as Adjunctive Treatments for Antibiotic Resistant Infections presented by Dr. Oreola Donini, Chief Scientific Officer, Soligenix, Inc.
  • Thermostable Subunit Vaccine Results in Protective Immunity in Rhesus Macaques in an Inhalational Ricin Model attended by Dr. Chad Roy, Director, Infectious Disease Aerobiology, Tulane National Primate Research Center, Associate Professor of Microbiology & Immunology, Tulane School of Medicine
  • Stability, Efficacy and Immunogenicity of a Third Generation Heat-Stable Anthrax Subunit Vaccine attended by Dr. Oreola Donini, Chief Scientific Officer, Soligenix, Inc.

The CBD S&T Research Conference is a forum for discussion between individuals conducting research to defend against bioterrorism and with the Defense Threat Reduction Agency (DTRA). Areas of specific interest include disease surveillance, characterization and point of need diagnostics, adaptive medical therapeutics and technology, rapid response and recovery science and technology and threat activity sensing and reporting. The conference offers business, learning and networking opportunities in the biodefense arena.

Tags: AnthraxBioterrorismBrucellaEventsRicin

Related Posts

DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies
Medical Countermeasures

NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies

January 12, 2023
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy